5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $6M | -$15M | 0.0% | -171.6% | -$9M | — | $6M |
| 2024 | $9M | -$9M | 0.0% | -95.6% | -$7M | — | $1M |
| 2023 | $3M | -$8M | 0.0% | -314.8% | -$6M | — | $3M |
| 2022 | $4803 | -$8M | 90.3% | -83511.5% | -$4M | — | $11M |
| 2021 | — | -$6M | — | — | — | — | $1M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$4M | 0.0% | -267.6% | -$3M | — | $3M |
| Dec '25 | $2M | -$3M | 0.0% | -196.9% | -$3M | — | $6M |
| Sep '25 | $1M | -$5M | 0.0% | -158.6% | -$2M | — | $8M |
| Jun '25 | $1M | -$4M | 0.0% | -198.2% | -$3M | — | $802835 |
| Mar '25 | $2M | -$3M | 0.0% | -141.7% | -$2M | — | $444706 |
| Dec '24 | $2M | -$3M | 0.0% | -133.5% | -$2M | — | $1M |
| Sep '24 | $2M | -$2M | 0.0% | -84.0% | -$2M | — | $756580 |
| Jun '24 | $2M | -$2M | 0.0% | -87.1% | -$2M | — | $801311 |
| Mar '24 | $2M | -$2M | 0.0% | -80.8% | -$2M | — | $2M |
| Dec '23 | $2M | -$2M | 0.0% | -105.8% | -$2M | — | $3M |
| Sep '23 | $298484 | -$2M | 75.0% | -768.7% | -$2M | — | $5M |
| Jun '23 | $19738 | -$2M | 93.7% | -9009.8% | -$1M | — | $8M |
| Mar '23 | $921 | -$2M | 90.6% | -169160.7% | -$2M | — | $10M |
| Dec '22 | $2346 | -$2M | 92.5% | -69213.2% | — | — | $11M |
| Sep '22 | $1150 | -$5M | 87.4% | -84883.1% | — | — | $13M |
| Jun '22 | $1306 | -$88052 | 88.8% | -52382.8% | — | — | — |
| Mar '22 | — | -$1M | — | — | — | — | — |
| Dec '21 | — | -$6M | — | — | — | — | $1M |
| Sep '21 | — | -$2M | — | — | — | — | — |
How the market has priced BIAF against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 4 years, bioAffinity Technologies, Inc.'s revenue has grown 986.6% per year. These are computed facts, not advice.
As of FY2025, bioAffinity Technologies, Inc. reported — of total debt against $6M of cash; operating income covered interest expense -238.3×.
In FY2025, gross margin was —, operating margin -171.6%, and net margin -242.0%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.